{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:33:11Z","timestamp":1773289991360,"version":"3.50.1"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bmcl.2021.128482","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T02:34:57Z","timestamp":1638412497000},"page":"128482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A survey of the clinical pipeline in neuroscience"],"prefix":"10.1016","volume":"56","author":[{"given":"Dean G.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike J.","family":"Wobst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2021.128482_b0005","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","article-title":"A Decade of FDA-Approved Drugs (2010\u20132019): trends and Future Directions","volume":"64","author":"Brown","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0010","unstructured":"Novel Drug Approvals for 2020. Published January 25, 2021. Accessed March 13, 2021. https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2020."},{"key":"10.1016\/j.bmcl.2021.128482_b0015","unstructured":"Setmelanotide \u2013 Highlights of Prescribing Information. Accessed September 22, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213793s000lbl.pdf."},{"key":"10.1016\/j.bmcl.2021.128482_b0020","unstructured":"Amisulpride \u2013 Highlights of Prescribing Information. Accessed September 22, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209510s000lbl.pdf."},{"key":"10.1016\/j.bmcl.2021.128482_b0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1358\/dot.2020.56.4.3107707","article-title":"Oliceridine, a G protein-selective ligand at the \u03bc-opioid receptor, for the management of moderate to severe acute pain","volume":"56","author":"Gan","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.bmcl.2021.128482_b0030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2021.128482_b0035","unstructured":"Remimazolam \u2013 Highlights of Prescribing Information. Accessed March 14, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212295s000lbl.pdf."},{"key":"10.1016\/j.bmcl.2021.128482_b0040","unstructured":"Inebilizumab-cdon \u2013 Highlights of Prescribing Information. Accessed March 14, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761142s000lbl.pdf."},{"key":"10.1016\/j.bmcl.2021.128482_b0045","unstructured":"Opicapone \u2013 Highlights of Prescribing Information. Accessed March 14, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212489s000lbl.pdf."},{"key":"10.1016\/j.bmcl.2021.128482_b0050","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmcl.2021.128482_b0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2021.128482_b0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40265-020-01300-4","article-title":"Eptinezumab: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2021.128482_b0065","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jpain.2012.03.009","article-title":"The economic costs of pain in the United States","volume":"13","author":"Gaskin","year":"2012","journal-title":"J Pain"},{"key":"10.1016\/j.bmcl.2021.128482_b0070","unstructured":"Understanding the Epidemic | CDC\u2019s Response to the Opioid Overdose Epidemic | CDC. Published September 9, 2021. Accessed April 21, 2021. https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html."},{"key":"10.1016\/j.bmcl.2021.128482_b0075","unstructured":"FDA approves Pfizer\u2019s LyricaTM for the treatment of the two most common forms of neuropathic pain. EurekAlert! Accessed September 9, 2021. https:\/\/www.eurekalert.org\/news-releases\/668491."},{"key":"10.1016\/j.bmcl.2021.128482_b0080","unstructured":"Cymbalta (duloxetine) FDA Approval History. Drugs.com. Accessed March 21, 2021. https:\/\/www.drugs.com\/history\/cymbalta.html."},{"key":"10.1016\/j.bmcl.2021.128482_b0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.bmcl.2021.128482_b0090","unstructured":"Lyrica Prescribing Information. Accessed March 21, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021446s036,022488s014lbl.pdf."},{"key":"10.1016\/j.bmcl.2021.128482_b0095","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acs.jmedchem.0c01886","article-title":"Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative","volume":"64","author":"Hammock","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0100","doi-asserted-by":"crossref","first-page":"115735","DOI":"10.1016\/j.bmc.2020.115735","article-title":"Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain","volume":"28","author":"Lee","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb1206","article-title":"An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer\u2019s disease","volume":"12","author":"Ghosh","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmcl.2021.128482_b0110","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1073\/pnas.94.4.1527","article-title":"Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons","volume":"94","author":"Toledo-Aral","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.bmcl.2021.128482_b0115","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1474-4422(14)70024-9","article-title":"Painful and painless channelopathies","volume":"13","author":"Bennett","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmcl.2021.128482_b0120","doi-asserted-by":"crossref","unstructured":"Kingwell K. Nav1.7 withholds its pain potential. Nat Rev Drug Discov. Published online April 8, 2019. doi: 10.1038\/d41573-019-00065-0.","DOI":"10.1038\/d41573-019-00065-0"},{"key":"10.1016\/j.bmcl.2021.128482_b0125","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.1021\/jm501981g","article-title":"Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications","volume":"58","author":"de Lera","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41583-021-00444-w","article-title":"The physiological function of different voltage-gated sodium channels in pain","volume":"22","author":"Goodwin","year":"2021","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmcl.2021.128482_b0135","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/j.pain.0000000000001227","article-title":"Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy","volume":"159","author":"McDonnell","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.bmcl.2021.128482_b0140","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-019-00807-3","article-title":"Safety, tolerability, and pharmacokinetics of GDC-0276, a novel NaV1.7 inhibitor, in a first-in-human, single- and multiple-dose study in healthy volunteers","volume":"39","author":"Rothenberg","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.bmcl.2021.128482_b0145","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1021\/acs.jmedchem.1c00049","article-title":"Discovery of acyl-sulfonamide Nav1.7 inhibitors GDC-0276 and GDC-0310","volume":"64","author":"Safina","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0150","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cell.2018.12.018","article-title":"Structural basis of Nav1.7 inhibition by a gating-modifier spider toxin","volume":"176","author":"Xu","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2021.128482_b0155","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1212\/WNL.0000000000002333","article-title":"Sodium channel Nav1.8: emerging links to human disease","volume":"86","author":"Han","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.bmcl.2021.128482_b0160","unstructured":"Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150 | Vertex Pharmaceuticals. Accessed March 15, 2021. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-positive-phase-2-data-third-proof-concept-study."},{"key":"10.1016\/j.bmcl.2021.128482_b0165","unstructured":"Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development | Vertex Pharmaceuticals. Accessed July 21, 2021. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-nav18-inhibitor-advancing-phase-2-clinical."},{"key":"10.1016\/j.bmcl.2021.128482_b0170","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nj7526-299a","article-title":"Neurodegenerative disease: brain windfall","volume":"515","author":"Gammon","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2021.128482_b0175","doi-asserted-by":"crossref","unstructured":"Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future. Med Res Rev. Published online February 11, 2020. doi: 10.1002\/med.2166.","DOI":"10.1002\/med.21661"},{"key":"10.1016\/j.bmcl.2021.128482_b0180","doi-asserted-by":"crossref","unstructured":"Devi G, Scheltens P. Heterogeneity of Alzheimer\u2019s disease: consequence for drug trials? Alzheimers Res Ther. 2018;10(1):122. doi: 10.1186\/s13195-018-0455-y.","DOI":"10.1186\/s13195-018-0455-y"},{"key":"10.1016\/j.bmcl.2021.128482_b0185","unstructured":"Cavazzoni P. The Path Forward: Advancing Treatments and Cures for Neurodegenerative Diseases \u2013 07\/29\/2021. FDA. Published July 29, 2021. Accessed September 11, 2021. https:\/\/www.fda.gov\/news-events\/congressional-testimony\/path-forward-advancing-treatments-and-cures-neurodegenerative-diseases-07292021."},{"key":"10.1016\/j.bmcl.2021.128482_b0190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrm3683","article-title":"Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death","volume":"14","author":"Ofengeim","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2021.128482_b0195","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41418-019-0408-4","article-title":"The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease","volume":"27","author":"O\u00f1ate","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bmcl.2021.128482_b0200","doi-asserted-by":"crossref","first-page":"E8788","DOI":"10.1073\/pnas.1714175114","article-title":"RIPK1 mediates a disease-associated microglial response in Alzheimer\u2019s disease","volume":"114","author":"Ofengeim","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.bmcl.2021.128482_b0205","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1126\/science.aaf6803","article-title":"RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS","volume":"353","author":"Ito","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2021.128482_b0210","doi-asserted-by":"crossref","unstructured":"Christofferson DE, Li Y, Hitomi J, et al. A novel role for RIP1 kinase in mediating TNF\u03b1 production. Cell Death Dis. 2012;3:e320. doi: 10.1038\/cddis.2012.64.","DOI":"10.1038\/cddis.2012.64"},{"key":"10.1016\/j.bmcl.2021.128482_b0215","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1021\/acs.jmedchem.6b01751","article-title":"Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases","volume":"60","author":"Harris","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0220","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02468-0","article-title":"A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis","volume":"23","author":"Weisel","year":"2021","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.bmcl.2021.128482_b0225","unstructured":"Our pipeline | GSK. Accessed July 7, 2021. https:\/\/www.gsk.com\/en-gb\/research-and-development\/our-pipeline\/."},{"key":"10.1016\/j.bmcl.2021.128482_b0230","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/acs.jmedchem.7b01647","article-title":"Discovery of 7-oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine derivatives as potent, orally available, and brain-penetrating receptor interacting protein 1 (RIP1) kinase inhibitors: analysis of structure-kinetic relationships","volume":"61","author":"Yoshikawa","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0235","unstructured":"After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer\u2019s Drug. BioSpace. Accessed March 20, 2021. https:\/\/www.biospace.com\/article\/denali-and-sanofi-pause-alzheimer-s-trial-and-pivot-to-another-drug\/."},{"key":"10.1016\/j.bmcl.2021.128482_b0240","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s40265-019-01139-4","article-title":"Recent Developments in LRRK2-Targeted Therapy for Parkinson\u2019s Disease","volume":"79","author":"Zhao","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.bmcl.2021.128482_b0245","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0250","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1021\/acsmedchemlett.5b00064","article-title":"Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor","volume":"6","author":"Hatcher","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2021.128482_b0255","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/jm5014055","article-title":"Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor","volume":"58","author":"Henderson","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0260","unstructured":"DNL201 | ALZFORUM. Accessed March 15, 2021. https:\/\/www.alzforum.org\/therapeutics\/dnl201."},{"key":"10.1016\/j.bmcl.2021.128482_b0265","unstructured":"Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson\u2019s Patients. Denali. Accessed September 11, 2021. https:\/\/www.denalitherapeutics.com\/investors\/press-release."},{"key":"10.1016\/j.bmcl.2021.128482_b0270","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149915","article-title":"p38 MAPKs - roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets","volume":"6","author":"Brennan","year":"2021","journal-title":"JCI Insight."},{"key":"10.1016\/j.bmcl.2021.128482_b0275","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2021.128482_b0280","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0624-8","article-title":"Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS","volume":"9","author":"Gibbs","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmcl.2021.128482_b0285","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.neuropharm.2009.11.010","article-title":"Targeting p38 MAPK pathway for the treatment of Alzheimer\u2019s disease","volume":"58","author":"Munoz","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2021.128482_b0290","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1021\/acs.jmedchem.9b00058","article-title":"A selective and brain penetrant p38\u03b1MAPK inhibitor candidate for neurologic and neuropsychiatric disorders that attenuates neuroinflammation and cognitive dysfunction","volume":"62","author":"Roy","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0295","unstructured":"In Phase 2 Trial, Neflamapimod Aids Cognition in Lewy Body Dementia | ALZFORUM. Accessed September 11, 2021. https:\/\/www.alzforum.org\/news\/conference-coverage\/phase-2-trial-neflamapimod-aids-cognition-lewy-body-dementia-0."},{"key":"10.1016\/j.bmcl.2021.128482_b0300","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1021\/acs.jmedchem.8b00370","article-title":"Dual leucine zipper kinase inhibitors for the treatment of neurodegeneration","volume":"61","author":"Siu","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0305","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1021\/acs.jmedchem.7b00843","article-title":"Selective inhibitors of dual leucine zipper kinase (DLK, MAP3K12) with activity in a model of Alzheimer\u2019s disease","volume":"60","author":"Patel","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0310","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fnagi.2020.00242","article-title":"Clinically precedented protein kinases: rationale for their use in neurodegenerative disease","volume":"12","author":"Benn","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.bmcl.2021.128482_b0315","unstructured":"Virtual meeting delivers first time drug structures. Accessed November 5, 2021. https:\/\/cen.acs.org\/acs-news\/acs-meeting-news\/Virtual-meeting-delivers-first-time-drug-structures\/99\/web\/2021\/04."},{"key":"10.1016\/j.bmcl.2021.128482_b0320","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2021.128482_b0325","unstructured":"Positive Phase 2 Results Claimed for Masitinib in Alzheimer\u2019s | ALZFORUM. Accessed March 15, 2021. https:\/\/www.alzforum.org\/news\/research-news\/positive-phase-2-results-claimed-masitinib-alzheimers."},{"key":"10.1016\/j.bmcl.2021.128482_b0330","doi-asserted-by":"crossref","unstructured":"Mora JS, Bradley WG, Chaverri D, et al. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther Adv Neurol Disord. 2021;14:17562864211030364. doi: 10.1177\/17562864211030365.","DOI":"10.1177\/17562864211030365"},{"key":"10.1016\/j.bmcl.2021.128482_b0335","unstructured":"AB halts masitinib trials after discovering heart disease worry. FierceBiotech. Accessed September 11, 2021. https:\/\/www.fiercebiotech.com\/biotech\/ab-halts-masitinib-trials-after-discovering-heart-disease-worry."},{"key":"10.1016\/j.bmcl.2021.128482_b0340","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson\u2019s disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.bmcl.2021.128482_b0345","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/jnnp.68.6.685","article-title":"Dopamine agonists: their role in the treatment of Parkinson\u2019s disease","volume":"68","author":"Brooks","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bmcl.2021.128482_b0350","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1021\/acs.jmedchem.9b01625","article-title":"Promiscuity of in vitro secondary pharmacology assays and implications for lead optimization strategies","volume":"63","author":"Brown","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0355","first-page":"37","article-title":"Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: a mini-review of clinical pharmacology","volume":"89","author":"Borovac","year":"2016","journal-title":"Yale J Biol Med."},{"key":"10.1016\/j.bmcl.2021.128482_b0360","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/acs.jmedchem.8b01767","article-title":"Novel strategies to activate the dopamine D1 receptor: recent advances in orthosteric agonism and positive allosteric modulation","volume":"62","author":"Hall","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0365","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1021\/acs.jmedchem.9b01234","volume":"62","author":"Hao","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0370","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1124\/jpet.116.236372","article-title":"An allosteric potentiator of the dopamine d1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis","volume":"360","author":"Svensson","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128482_b0375","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1021\/acschemneuro.9b00589","article-title":"D1 agonist improved movement of parkinsonian nonhuman primates with limited dyskinesia side effects","volume":"11","author":"Young","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmcl.2021.128482_b0380","doi-asserted-by":"crossref","unstructured":"Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray D. PF-06649751 efficacy and safety in early Parkinson\u2019s disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord. 2020;13:1756286420911296. doi: 10.1177\/1756286420911296.","DOI":"10.1177\/1756286420911296"},{"key":"10.1016\/j.bmcl.2021.128482_b0385","unstructured":"Therapeutics C. Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson\u2019s Disease. GlobeNewswire News Room. Published October 30, 2020. Accessed March 15, 2021. https:\/\/www.globenewswire.com\/news-release\/2020\/10\/30\/2117657\/0\/en\/Cerevel-Therapeutics-Announces-First-Patients-Dosed-in-all-Phase-3-Trials-of-Tavapadon-for-the-Treatment-of-Parkinson-s-Disease.html."},{"key":"10.1016\/j.bmcl.2021.128482_b0390","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41386-020-00908-0","article-title":"Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia","volume":"46","author":"Desai","year":"2021","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.bmcl.2021.128482_b0395","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2021.128482_b0400","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.bmcl.2021.128482_b0405","unstructured":"FDA Grants Accelerated Approval for Alzheimer\u2019s Drug. FDA. Published June 7, 2021. Accessed July 1, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug."},{"key":"10.1016\/j.bmcl.2021.128482_b0410","unstructured":"Aducanumab-avwa \u2013 Highlights of Prescribing Information. Accessed September 22, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761178s000lbl.pdf."},{"key":"10.1016\/j.bmcl.2021.128482_b0415","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/d41586-021-01763-9","article-title":"Controversial Alzheimer\u2019s drug approval could affect other diseases","volume":"595","author":"Mullard","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2021.128482_b0420","unstructured":"Tofersen for ALS Clears Phase 1\/2 Trial, Now in Phase 3. Mass General Advances in Motion. Accessed September 22, 2021. https:\/\/advances.massgeneral.org\/neuro\/journal.aspx?id=1699."},{"key":"10.1016\/j.bmcl.2021.128482_b0425","unstructured":"Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS. Accessed November 5, 2021. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-announces-topline-results-tofersen-phase-3-study-and-its."},{"key":"10.1016\/j.bmcl.2021.128482_b0430","unstructured":"Nonprofit Partnership Spurs Phase 3 Clinical Trial for Patients With Rare Genetic Form Of ALS. The ALS Association. Accessed September 12, 2021. https:\/\/www.als.org\/blog\/nonprofit-partnership-spurs-phase-3-clinical-trial-patients-rare-genetic-form-als."},{"key":"10.1016\/j.bmcl.2021.128482_b0435","unstructured":"Genentech Provides Update on Tominersen Program in Manifest Huntington\u2019s Disease. Published March 22, 2021. Accessed September 12, 2021. https:\/\/www.businesswire.com\/news\/home\/20210322005754\/en\/Genentech-Provides-Update-on-Tominersen-Program-in-Manifest-Huntingtons-Disease."},{"key":"10.1016\/j.bmcl.2021.128482_b0440","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.9b00322","article-title":"Design and identification of a novel, functionally subtype selective GABAA positive allosteric modulator (PF-06372865)","author":"Owen","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0445","doi-asserted-by":"crossref","first-page":"108333","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2021.128482_b0450","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2021.128482_b0455","unstructured":"Inc B. Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder. GlobeNewswire News Room. Published June 15, 2021. Accessed July 11, 2021. https:\/\/www.globenewswire.com\/news-release\/2021\/06\/15\/2247077\/0\/en\/Sage-Therapeutics-and-Biogen-Announce-Positive-Pivotal-Phase-3-Results-for-Zuranolone-an-Investigational-Two-Week-Once-Daily-Therapeutic-Being-Evaluated-for-Major-Depressive-Disord.html."},{"key":"10.1016\/j.bmcl.2021.128482_b0460","unstructured":"Sage Therapeutics\/Biogen\u2019s zuranolone | FierceBiotech. Accessed March 15, 2021. https:\/\/www.fiercebiotech.com\/special-report\/sage-therapeutics-biogen-s-zuranolone-fierce-biotech-s-top-10-data-readouts-2021."},{"key":"10.1016\/j.bmcl.2021.128482_b0465","unstructured":"Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy. Accessed November 5, 2021. https:\/\/www.biospace.com\/article\/releases\/ganaxolone-achieves-primary-endpoint-in-phase-3-trial-for-cdkl5-deficiency-disorder-cdd-a-rare-form-of-genetic-epilepsy\/."},{"key":"10.1016\/j.bmcl.2021.128482_b0470","unstructured":"FDA Rejects Nuplazid for Alzheimer\u2019s, Other Dementia-related Psychosis. Accessed September 12, 2021. https:\/\/alzheimersnewstoday.com\/2021\/04\/05\/fda-rejects-nuplazid-acadia-dementia-related-psychosis-treatment\/."},{"key":"10.1016\/j.bmcl.2021.128482_b0475","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1517\/14656566.2013.819345","article-title":"Pimavanserin for the treatment of Parkinson\u2019s disease psychosis","volume":"14","author":"Friedman","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmcl.2021.128482_b0480","unstructured":"Summary of Antiepileptic Drugs | Epilepsy Foundation. Accessed March 20, 2021. https:\/\/www.epilepsy.com\/article\/2014\/3\/summary-antiepileptic-drugs."},{"key":"10.1016\/j.bmcl.2021.128482_b0485","unstructured":"Drug-Resistant Epilepsy. Epilepsy Foundation. Accessed March 20, 2021. https:\/\/www.epilepsy.com\/learn\/drug-resistant-epilepsy."},{"key":"10.1016\/j.bmcl.2021.128482_b0490","doi-asserted-by":"crossref","first-page":"12228","DOI":"10.1021\/acs.jmedchem.1c00864","article-title":"Discovery of soticlestat, a potent and selective inhibitor for cholesterol 24-hydroxylase (CH24H)","volume":"64","author":"Koike","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128482_b0495","doi-asserted-by":"crossref","first-page":"E464","DOI":"10.3390\/biom10030464","article-title":"Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors","volume":"10","author":"Hanada","year":"2020","journal-title":"Biomolecules."},{"key":"10.1016\/j.bmcl.2021.128482_b0500","unstructured":"PhD MF. Soticlestat Reduces Dravet Seizure Frequency in Children, Data Show. Accessed March 15, 2021. https:\/\/dravetsyndromenews.com\/2020\/09\/08\/soticlestat-reduces-seizure-frequency-in-children-with-dravet-syndrome-top-line-data-show\/."},{"key":"10.1016\/j.bmcl.2021.128482_b0505","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coph.2005.11.001","article-title":"Glutamate-based therapeutic approaches: NR2B receptor antagonists","volume":"6","author":"Gogas","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bmcl.2021.128482_b0510","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/acn3.50998","article-title":"Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome","volume":"7","author":"Auvin","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.bmcl.2021.128482_b0515","unstructured":"Setback for Forest Labs, as radiprodil disappoints in mid-stage pain trial. Accessed July 3, 2021. https:\/\/www.thepharmaletter.com\/article\/setback-for-forest-labs-as-radiprodil-disappoints-in-mid-stage-pain-trial."},{"key":"10.1016\/j.bmcl.2021.128482_b0520","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/13543776.2019.1637421","article-title":"mGluR2 positive allosteric modulators: an updated patent review (2013\u20132018)","volume":"29","author":"Trabanco","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2021.128482_b0525","unstructured":"Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy. Addex therapeutics. Accessed July 21, 2021. https:\/\/www.addextherapeutics.com\/en\/investors\/press-releases\/addex-starts-phase-2-clinical-study-adx71149-epilepsy\/."},{"key":"10.1016\/j.bmcl.2021.128482_b0530","unstructured":"Epilepsy Pipeline Tracker. Epilepsy Foundation. Accessed March 16, 2021. https:\/\/www.epilepsy.com\/pipeline-listing-page."},{"key":"10.1016\/j.bmcl.2021.128482_b0535","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bcp.12618","article-title":"CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment","volume":"80","author":"Edvinsson","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2021.128482_b0540","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12426-9","article-title":"First-in-human trial of blood\u2013brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound","volume":"10","author":"Abrahao","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2021.128482_b0545","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1248\/cpb.c19-00854","article-title":"Smart strategies for therapeutic agent delivery into brain across the blood-brain barrier using receptor-mediated transcytosis","volume":"68","author":"Tashima","year":"2020","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmcl.2021.128482_b0550","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/biom11081131","article-title":"Transportation of Single-Domain Antibodies through the Blood-Brain Barrier","volume":"11","author":"Ruiz-L\u00f3pez","year":"2021","journal-title":"Biomolecules."},{"key":"10.1016\/j.bmcl.2021.128482_b0555","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2021.128482_b0560","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","article-title":"An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders","volume":"16","author":"Ashton","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"10.1016\/j.bmcl.2021.128482_b0565","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","article-title":"Animal models of neurodegenerative diseases","volume":"21","author":"Dawson","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bmcl.2021.128482_b0570","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1474-4422(14)70129-2","article-title":"Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?","volume":"13","author":"Mitsumoto","year":"2014","journal-title":"Lancet Neurol"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21007095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21007095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:43:17Z","timestamp":1760773397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X21007095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":114,"alternative-id":["S0960894X21007095"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128482","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A survey of the clinical pipeline in neuroscience","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128482"}}